Matthew P. Connor, MD

Faramand RG, Zhang A, Roloff GW, Aldoss I, Advani AS, Battiwalla M, Boccucci J, Byrd K, Cassaday RD, Connor M, Dykes KC, Hilal T, Kopmar NE, Kota VK, Lee CJ, Leonard JT, Lill GR, Lin C, Logan AC, Majhail NS, Malik SA, McCauley R, Moore J, Mountjoy L, O'Connor T, O'Dwyer KM, Bobillo SO, Oliai CH, Othman T, Ramakrishnan A, Sandhu K, Schwartz M, Shaughnessy P, Srinagesh HK, Sutherland KC, Tan V, Tsai SB, Ulrickson M, Wang ES, Yaghmour G, Frey NV, Shah BD, Muffly LS Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia: Results from the Real-World Outcomes Collaborative of Chimeric Antigen Receptor T in Adult Acute Lymphoblastic Leukemia , Transplant Cell Ther: 2026

Othman T, Roloff GW, Miller K, Zhang A, Sutherland KC, Faramand R, Hill LC, Muhsen IN, Jeyakumar N, Ladha A, Sasine J, Lin C, Kopmar NE, Tsai SB, O'Connor TE, Hilal T, Solh MM, Guzowski C, Tan V, Majhail NS, Battiwalla M, Malik S, Mathews J, Shaughnessy P, Mountjoy L, Dykes KC, Logan AC, Schwartz M, Connor MP, Wang J, Vasu S, Kumaran M, Hoeg R, Tracy SI, Yalniz F, Yaghmour G, Pullarkat V, Cassaday RD, Leonard JT, Shah BD, Frey NV, Muffly LS, Aldoss I Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL , Blood Adv: 2026

Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Odstrcil Bobillo S, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL , Blood, 147(17): 2026,2011–2017

Connor MP, Barsouk A, Elghawy O, Lai C Advancements in targeted therapies for acute myeloid leukemia , Curr Opin Pharmacol, 87: 2026

Kopmar NE, Gooley TA, Roloff GW, Zhang A, Aldoss I, Lin C, Bezerra E, Muhsen I, Jeyakumar N, Dykes KC, O'Connor T, Tang K, Chen EC, Connor M, Frey NV, Gordillo CA, Hilal T, Al Darobi AH, Hoeg RT, Irizarry Gatell VM, Valtis YK, Jackson CW, Kota VK, Koura D, Boccucci J, Guzowski C, Kumaran MV, Ladha A, Lee CJ, Majhail NS, Malik SA, Mathews J, Miller K, Moore J, Mountjoy L, O'Dwyer KM, Odstrcil Bobillo S, Oliai CH, Oluwole OO, Pradeep R, Othman T, Ramakrishnan A, Reshef R, Sasine J, Vasu S, Schwartz M, Shaughnessy P, Stefan M, Stock W, Sutherland KC, Tan V, Solh MM, Tracy S, Luskin M, Logan AC, Leonard JT, Hill L, Tsai SB, Advani AS, Ulrickson M, Bachanova V, Dholaria B, Park JH, Battiwalla M, Faramand R, Shah BD, Yaghmour G, Muffly LS, Cassaday RD Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia , Blood Immunology & Cellular Therapy, 2(1): 2026,100028

Kopmar NE, Gooley TA, Roloff GW, Zhang A, Aldoss I, Lin C, Bezerra E, Muhsen I, Jeyakumar N, Dykes KC, O'Connor T, Tang K, Chen EC, Connor M, Frey NV, Gordillo CA, Hilal T, Al Darobi AH, Hoeg RT, Irizarry Gatell VM, Valtis YK, Jackson CW, Kota VK, Koura D, Boccucci J, Guzowski C, Kumaran MV, Ladha A, Lee CJ, Majhail NS, Malik SA, Mathews J, Miller K, Moore J, Mountjoy L, O'Dwyer KM, Odstrcil Bobillo S, Oliai CH, Oluwole OO, Pradeep R, Othman T, Ramakrishnan A, Reshef R, Sasine J, Vasu S, Schwartz M, Shaughnessy P, Stefan M, Stock W, Sutherland KC, Tan V, Solh MM, Tracy S, Luskin M, Logan AC, Leonard JT, Hill L, Tsai SB, Advani AS, Ulrickson M, Bachanova V, Dholaria B, Park JH, Battiwalla M, Faramand R, Shah BD, Yaghmour G, Muffly LS, Cassaday RD Toxicity of Brexucabtagene Autoleucel as a Standard Therapy for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia , Blood Immunol Cell Ther: 2025

Logan A, Yalniz F, Zhang A, Miller K, Sutherland K, Jeyakumar N, Srinagesh H, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Sasine J, Hill L, Muhsen I, Advani A, Aldoss I, Othman T, Sandhu K, Reshef R, , Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Valtis Y, Vasu S, Bezerra E, Wang E, Leonard J, Tan V, O'Dwyer K, Moore J, McCauley R, Majhail N, Mountjoy L, Ramakrishnan A, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Roloff G, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Daunov M, Byrd K, Bachanova V, Tracy S, Grover P, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Faramand R, Muffly L Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world , Blood, 146(Supplement 1): 2025,516

Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, Miller K, Zhang A, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Hill L, Muhsen I, Sasine J, Advani A, Sandhu K, Reshef R, Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Vasu S, Bezerra E, O'Dwyer K, Moore J, Wang E, McCauley R, Majhail N, Ramakrishnan A, Mountjoy L, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Srinagesh H, Sutherland K, Jamy O, Mohty R, Kumaran M, Hoeg R, Oliai C, Lill G, Stock W, Schwartz M, Othman T, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Bachanova V, Tracy S, Grover P, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Frey N, Muffly L, Shah B, Aldoss, I KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel) , Blood, 146(Supplement 1): 2025,3365

Svoboda J, Schuster S, Porter D, Cook M, Nasta SD, Landsburg D, Barta S, Ruella M, Chong E, Carter J, Thomas C, Tomasulo E, Frey N, Connor M, Shea J, Cervini A, McConville J, Tongue C, Four M, Marshall A, Hwang W, Leskowitz R, Gonzalez V, Christensen S, Plesa G, Siegel D, Jadlowsky J, Fraietta J, Levine B, Hexner E, June C IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure , Blood, 146(Supplement 1): 2025,2394

Valtis Y, Sandhu K, Faramand R, Zhang A, Miller K, Hill L, Muhsen I, Othman T, Luskin M, Chen E, Oliai C, Lill G, Cassaday R, Kopmar N, Logan A, Connor M, Hilal T, Park J, Solh M, Guzowski C, Leonard J, Tan V, Jeyakumar N, Srinagesh H, Kumaran M, Hoeg R, Koura D, Dykes K, Stock W, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, O'Dwyer K, Moore J, Ulrickson M, Al-Darobi A, Byrd K, Tsai S, O'Connor T, Wang E, McCauley R, Jamy O, Mohty R, Roloff G, Sutherland K, Aldoss I, Shah B, Muffly L, Frey N Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis , Blood, 146(Supplement 1): 2025,2715